NCT04903054View on ClinicalTrials.gov

Selective CD28 Blockade in Renal Transplant Recipients

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 10, 2022

Primary Completion Date

September 22, 2022

Study Completion Date

September 22, 2022

Conditions
Kidney TransplantationRenal Transplant Recipients
Interventions
BIOLOGICAL

Lulizumab

Lulizumab is a pegylated, humanized monovalent domain antibody construct that is specific for human cluster of differentiation CD28.

DRUG

Tacrolimus

Standard of Care: Renal transplant rejection prophylaxis.

BIOLOGICAL

Thymoglobulin®

Standard of Care: Renal transplant rejection prophylaxis.

DRUG

Methylprednisolone

Standard of Care: Renal transplant rejection prophylaxis.

DRUG

Mycophenolate Mofetil

Standard of Care: Renal transplant rejection prophylaxis.

DRUG

Prednisone

Standard of Care: Renal transplant rejection prophylaxis.

Trial Locations (1)

30332

Emory University Hospital, Atlanta

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

PPD Development, LP

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT04903054 - Selective CD28 Blockade in Renal Transplant Recipients | Biotech Hunter | Biotech Hunter